Resverlogix Corp RVXCF

Primary Symbol: T.RVX

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Sarah gone, dr wong gone

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Aug 29, 2022 10:52am

250 Views

Post# 34926627

RE:RE:Sarah gone, dr wong gone

narmac, " Hepalink cleaning out some insiders setting up for their major move I assume."

As long as they're willing to pay a fair price for the 64 % of RVX stock they don't own. And let it be the final solution for RVX stockholders and be done with it.

But then there is Eastern, Ori and other major insiders, that will vote it down.

jmo
G1945V

<< Previous

Bullboard Posts

Next >>

One of the strongest contenders to lead Canada’s cannabis market